Tokyo, Japan

Shingo Hanaoka

USPTO Granted Patents = 5 

 

 

Average Co-Inventor Count = 4.0

ph-index = 1


Location History:

  • Kashiwa, JP (2021)
  • Tokyo, JP (2019 - 2022)
  • Chiba, JP (2013 - 2023)

Company Filing History:


Years Active: 2013-2023

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Shingo Hanaoka: Innovator in Cancer Treatment

Introduction

Shingo Hanaoka is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of cancer research and treatment. With a total of 5 patents to his name, Hanaoka is recognized for his innovative approaches to developing anticancer drugs and testing methods.

Latest Patents

Hanaoka's latest patents include the development of an anti-TMEM-180 antibody, which serves as an anticancer drug and a cancer testing method. The objective of this invention is to provide a drug capable of treating cancer by identifying a target molecule specifically expressed in cancer cells. This drug acts specifically on the target molecule, enhancing its effectiveness. Additionally, the cancer testing method involves measuring the target molecule in a sample collected from a subject. The anticancer drug contains an anti-transmembrane protein 180 (TMEM-180) antibody or an antigen-binding fragment thereof.

Career Highlights

Throughout his career, Shingo Hanaoka has worked with notable organizations such as Rin Institute Inc. and the National Cancer Center Japan. His work has focused on advancing cancer treatment methodologies and improving patient outcomes through innovative drug development.

Collaborations

Hanaoka has collaborated with esteemed colleagues, including Yasuhiro Matsumura and Masahiro Yasunaga. These partnerships have contributed to the success of his research and the development of his patents.

Conclusion

Shingo Hanaoka is a dedicated inventor whose work in cancer treatment has the potential to make a significant impact on the medical field. His innovative patents and collaborations highlight his commitment to advancing cancer research and improving therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…